Brief: Rein Therapeutics Receives European Regulatory Approval To Initiate Phase 2 Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
09/10/2025 12:35
Oct 9 (Reuters) - Rein Therapeutics Inc RNTX.O: REIN THERAPEUTICS RECEIVES EUROPEAN REGULATORY APPROVAL TO INITIATE PHASE 2 TRIAL OF LTI-03 IN IDIOPATHIC PULMONARY FIBROSIS Source text: ID:nGNXbfzcWZ Further company coverage: RNTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering